PP
OPTN

Paloma Partners’s OptiNose OPTN Stock Holding History

Paloma Partners’s Portfolio OPTN Stock Details OPTN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,543
Closed -$86.5K – 1539
2024
Q2 		$86.5K Buy
+5,543
New +$92.9K ﹤0.01% 1091
2020
Q1 		– Sell
-1,349
Closed -$187K – 1839
2019
Q4 		$187K Buy
+1,349
New +$175K ﹤0.01% 1984

Other funds holding OPTN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
MP
MVM Partners Boston, Massachusetts $10.8M AUM 61.97% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Paloma Partners's OPTN Position: Q3 2024 in Review

Paloma Partners sold out of OptiNose (OPTN) in Q3 2024, closing a stake of 5,543 shares — an estimated $86.5K sold.

Paloma Partners first reported a position in OPTN in Q4 2019 and held it in 2 quarters. The position peaked at $187K in Q4 2019. 65 funds tracked by Wall St. Rank hold OPTN as of Q3 2024.

  • Paloma Partners reported no remaining OptiNose position as of Q3 2024 after selling out during the quarter.
  • Paloma Partners sold 5,543 OptiNose shares in Q3 2024, an estimated $86.5K.
  • Paloma Partners first reported a position in OptiNose in Q4 2019 and held it in 2 quarters.
  • Paloma Partners's OptiNose position peaked at $187K in Q4 2019.
  • 65 funds tracked by Wall St. Rank held OptiNose as of Q3 2024.

Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.